Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®

An Open Label, Multicenter, Dose Finding, Single Arm, Phase 1 Study of Fusilev® (Levoleucovorin) to Prevent or Reduce Mucositis in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer Receiving Folotyn® (Pralatrexate)

To determine the optimal dose and schedule of Fusilev to prevent or reduce Folotyn-related Grade 3 or higher oral mucositis in patients with Non-Small Cell Lung Cancer.

Study Overview

• Status: Withdrawn
• Conditions: Non-Small Cell Lung Cancer
• Intervention / Treatment: Drug: Folotyn; Drug: Fusilev

Detailed Description

This is an open-label, uncontrolled, nonrandomized, multicenter, dose-finding, single-arm, Phase 1 study primarily to determine the optimal dose and schedule of Fusilev to prevent or reduce Folotyn-related Grade 3 or higher oral mucositis.

• Study Type: Interventional
• Phase: Phase 1

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• At least 18 years of age
• Relapsed or Refractory Non Small Cell Lung Cancer (NSCLC) after at least one line of therapy
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
• Histologically or cytologically confirmed Stage III B/IV NSCLC
• Adequate hematological, hepatic, and renal function
• Available during the first 8 weeks of the study treatment period to visit the clinic for oral Mucositis assessments on scheduled days

Exclusion Criteria:

• Active concurrent malignancy. If there is a history of prior malignancies other than those exceptions listed above, the patient must be disease-free for at least 5 years
• Congestive heart failure
• Uncontrolled hypertension
• Known human immunodeficiency virus (HIV)-positive diagnosis
• Previous exposure to Pralatrexate
• Pregnant or breast-feeding women
• Major surgery within 14 days of enrollment
• Active uncontrolled infection, underlying medical condition, or other serious illness that would impair the ability of the patient to receive protocol treatment
• Symptomatic central nervous system (CNS) metastases or lesions for which treatment is required. Patients who received prophylactic CNS treatment are eligible

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

5

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cohort 1 - Fusilev - 20 doses; 5 mg/m2 QID (6 hours apart) starting on Days 2 and 16 (24 hours after Folotyn dose) for a total of 20 doses in a 28-day cycle Days 2 and 16: 4 doses/day Days 3 and 17: 4 doses/day Days 4 and 18: 2 doses/day Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle	Drug: Folotyn; A cycle of Folotyn treatment is 28 days, with treatment on Days 1 and 15 in each cycle.; Other Names: Pralatrexate; Drug: Fusilev; Fusilev will be administered either four times a day (QID) (6 hours apart, ±10 minutes), twice a day (BID) (8 hours apart, ±10 minutes) or once a day (QD) by IV push (3-5 minutes) at a dose of 5 mg/m2 according to the cohort to which patients are assigned.; Other Names: Levoleucovorin
Experimental: Cohort 2 - Fusilev - 12 doses; 5 mg/m2 BID 8 hours apart on Days 2, 3, 4, 16, 17, and 18 for a total of 12 doses in a 28-day cycle. Fusilev dose to start 24 hours after Folotyn dose. Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle	Drug: Folotyn; A cycle of Folotyn treatment is 28 days, with treatment on Days 1 and 15 in each cycle.; Other Names: Pralatrexate; Drug: Fusilev; Fusilev will be administered either four times a day (QID) (6 hours apart, ±10 minutes), twice a day (BID) (8 hours apart, ±10 minutes) or once a day (QD) by IV push (3-5 minutes) at a dose of 5 mg/m2 according to the cohort to which patients are assigned.; Other Names: Levoleucovorin
Experimental: Cohort 3 - Fusilev - 8 doses; 5 mg/m2 BID 8 hours apart on Days 2, 3, 16, and 17 for a total of 8 doses in a 28-day cycle. Fusilev dose to start 24 hours after Folotyn dose. Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle	Drug: Folotyn; A cycle of Folotyn treatment is 28 days, with treatment on Days 1 and 15 in each cycle.; Other Names: Pralatrexate; Drug: Fusilev; Fusilev will be administered either four times a day (QID) (6 hours apart, ±10 minutes), twice a day (BID) (8 hours apart, ±10 minutes) or once a day (QD) by IV push (3-5 minutes) at a dose of 5 mg/m2 according to the cohort to which patients are assigned.; Other Names: Levoleucovorin
Experimental: Cohort 4 - Fusilev - 4 doses; 5 mg/m2 BID 8 hours apart on Days 2 and 16 for a total of 4 doses in a 28-day cycle. Fusilev dose to start 24 hours after Folotyn dose. Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle	Drug: Folotyn; A cycle of Folotyn treatment is 28 days, with treatment on Days 1 and 15 in each cycle.; Other Names: Pralatrexate; Drug: Fusilev; Fusilev will be administered either four times a day (QID) (6 hours apart, ±10 minutes), twice a day (BID) (8 hours apart, ±10 minutes) or once a day (QD) by IV push (3-5 minutes) at a dose of 5 mg/m2 according to the cohort to which patients are assigned.; Other Names: Levoleucovorin
Experimental: Cohort 5 - Fusilev - 2 doses; 5 mg/m2 once on Days 2 and 16 for a total of 2 doses in a 28-day cycle Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle	Drug: Folotyn; A cycle of Folotyn treatment is 28 days, with treatment on Days 1 and 15 in each cycle.; Other Names: Pralatrexate; Drug: Fusilev; Fusilev will be administered either four times a day (QID) (6 hours apart, ±10 minutes), twice a day (BID) (8 hours apart, ±10 minutes) or once a day (QD) by IV push (3-5 minutes) at a dose of 5 mg/m2 according to the cohort to which patients are assigned.; Other Names: Levoleucovorin

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Optimal dose and Schedule of Fusilev to prevent or reduce Oral Mucositis	The study period will begin on the first day of Folotyn treatment (Day 1). Folotyn will be administered intravenously (IV) at a dose of 190 mg/m2 on Days 1 and 15 in a 28-day treatment cycle. Twenty-four hours after the Folotyn dose, Fusilev will be administered either four times a day (QID) (6 hours apart, ±10 minutes), twice a day (BID) (8 hours apart, ±10 minutes) or once a day (QD) by IV push (3-5 minutes) at a dose of 5 mg/m2 according to the cohort to which patients are assigned. Within a given cohort, Fusilev will be administered at the same dose and schedule after each Folotyn dose for the duration of the study.	Up to 8 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Impact of Fusilev on the number of Folotyn-related dose modifications secondary to oral mucositis	Analysis will involve the number, percent and type of Folotyn dose modification as a function of Fusilev dose.	Up to 8 weeks
Impact of Fusilev on the frequency of Oral Mucositis	Distribution of the number of cases of oral mucositis will be described by cohort and by degree of mucositis.	Up to 8 weeks
Impact of Fusilev on use of Analgesics for Oral Mucositis	Oral mucositis assessment form will be provided by the sponsor and is to be completed during treatment visits on day 1 & 15, days 4 &18, end of treatment visits. Patients will complete an Oral Mucositis Daily Questionnaire (OMDQ) starting at Day 1 of Cycle 1 and ending at the End of Treatment visit. Oral mucositis assessment will be assessed in the clinic by the investigator, or designee, and graded according to AE severity as established in the NCI CTCAE scale, Version 4.0.	Up to 8 weeks
Impact of Fusilev on number of Folotyn doses delivered	All treatment-emergent AEs will be managed per the investigator's judgment or the site's clinical standard of care. Folotyn decrease dose modifications will be made based on Hematologic Adverse Events (absolute neutrophil count) and Non- Hematologic Adverse events (CTCAE v.4) excluding nausea/vomiting for dose adjustments	Up to 8 weeks

Collaborators and Investigators

• Sponsor: Acrotech Biopharma Inc.

Study record dates

Study Major Dates

• Study Start: April 1, 2013
• Primary Completion (Anticipated): April 1, 2015
• Study Completion (Anticipated): April 1, 2015

Study Registration Dates

• First Submitted: March 21, 2013
• First Submitted That Met QC Criteria: March 25, 2013
• First Posted (Estimate): March 28, 2013

Study Record Updates

• Last Update Posted (Actual): January 23, 2020
• Last Update Submitted That Met QC Criteria: January 21, 2020
• Last Verified: January 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Respiratory Tract Diseases; Neoplasms; Lung Diseases; Neoplasms by Site; Gastrointestinal Diseases; Respiratory Tract Neoplasms; Thoracic Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Gastroenteritis; Stomatognathic Diseases; Mouth Diseases; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Mucositis; Physiological Effects of Drugs; Protective Agents; Antidotes; Levoleucovorin
• Other Study ID Numbers: SPI-FUS-12-103